Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation.

Publication Type:

Journal Article

Authors:

Yu, Evan Y; Gulati, Roman; Telesca, Donatello; Jiang, Peter; Tam, Stephen; Russell, Kenneth J; Nelson, Peter S; Etzioni, Ruth; Higano, Celestia S

Source:

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 28, Issue 16, p.2668-73 (2010)

Keywords:

2010, Aged, Aged, 80 and over, Analysis of Variance, Androgen Antagonists, Antineoplastic Agents, Hormonal, Brachytherapy, Castration, Cause of Death, Center-Authored Paper, Chemotherapy, Adjuvant, Confidence Intervals, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Flutamide, Follow-Up Studies, Human Biology Division, Humans, Immunohistochemistry, Kaplan-Meier Estimate, Leuprolide, Male, Middle Aged, Multivariate Analysis, Neoplasm Recurrence, Local, Neoplasm Staging, Probability, Prospective Studies, Prostate-Specific Antigen, PROSTATECTOMY, Prostatic Neoplasms, Public Health Sciences Division, Risk Assessment, Salvage Therapy, Survival Analysis, Time Factors, Treatment Outcome

Abstract:

This was an exploratory analysis of a trial of intermittent androgen deprivation (IAD) in men with biochemical relapse (BR) to establish first cycle characteristics prognostic for progression to castration-resistant prostate cancer (CRPC) and death.